96 related articles for article (PubMed ID: 21804582)
1. PI3K pathway inhibitors approach junction.
Holmes D
Nat Rev Drug Discov; 2011 Aug; 10(8):563-4. PubMed ID: 21804582
[No Abstract] [Full Text] [Related]
2. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
3. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
5. [PI3K inhibitor].
Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions.
Bartlett JM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S86-95. PubMed ID: 21115427
[TBL] [Abstract][Full Text] [Related]
7. From the bench to the bed side: PI3K pathway inhibitors in clinical development.
Maira SM; Finan P; Garcia-Echeverria C
Curr Top Microbiol Immunol; 2010; 347():209-39. PubMed ID: 20582534
[TBL] [Abstract][Full Text] [Related]
8. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma.
King D; Yeomanson D; Bryant HE
J Pediatr Hematol Oncol; 2015 May; 37(4):245-51. PubMed ID: 25811750
[TBL] [Abstract][Full Text] [Related]
9. Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.
Carlson CB; Robers MB; Vogel KW; Machleidt T
J Biomol Screen; 2009 Feb; 14(2):121-32. PubMed ID: 19196698
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of phosphatidylinositol 3-kinase and mTOR but not Akt enhance replication of bovine ephemeral fever virus.
Ji WT; Wang YC; Lin FL; Liao MH; Shih WL; Liu HJ
Vet J; 2011 Jan; 187(1):119-23. PubMed ID: 20074986
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
12. Target of rapamycin signaling in leukemia and lymphoma.
Vu C; Fruman DA
Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
[TBL] [Abstract][Full Text] [Related]
13. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia].
Dos Santos C; Récher C; Demur C; Payrastre B
Bull Cancer; 2006 May; 93(5):445-7. PubMed ID: 16777621
[TBL] [Abstract][Full Text] [Related]
14. Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.
Juric D; Baselga J
J Clin Oncol; 2012 Mar; 30(8):765-6. PubMed ID: 22271482
[No Abstract] [Full Text] [Related]
15. Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy.
Zhao YW; Jin L; Li ZM; Zhao CJ; Wei YQ; Yang HS
Cancer Sci; 2011 Aug; 102(8):1469-75. PubMed ID: 21561530
[TBL] [Abstract][Full Text] [Related]
16. Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness.
Rodon J; Tabernero J
Cancer Discov; 2017 Jul; 7(7):666-669. PubMed ID: 28684409
[TBL] [Abstract][Full Text] [Related]
17. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
19. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex.
Sui L; Wang J; Li BM
Learn Mem; 2008 Oct; 15(10):762-76. PubMed ID: 18832563
[TBL] [Abstract][Full Text] [Related]
20. BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds.
Carlson CB; Mashock MJ; Bi K
J Biomol Screen; 2010 Mar; 15(3):327-34. PubMed ID: 20145103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
